We previously showed that NKG2DL expression is significantly upregulated on TMZ-resistant GBM cell lines during the first 12 h following TMZ exposure and that a synergistic tumor killing effect could be achieved in vitro by combining simultaneous exposure of TMZ-resistant GBM cell lines to therapeutic concentrations of TMZ and MGMT-modified γδ T cells12. The gene discussed is MGMT; the disease is glioblastoma.